Mice with the L162R mutation showed enhanced BCR/NF-κB signaling, abnormal B cell differentiation, enhanced germinal center formation, and late development of a CLL-like disease at age 18–24 mo. Here, NFKB1 is linked to B-cell chronic lymphocytic leukemia.